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Many facets of tissue engineered models aim to understand cellular mechanisms to 
recapitulate in vivo behavior, study and mimic diseases for drug interventions and to 
provide better understanding towards improving regenerative medicine. Recent and rapid 
advances in stem cell biology, material science and engineering, have made the generation 
of complex engineered tissues much more attainable. One such tissue, human 
myocardium; is extremely intricate, with a number of different cell types. Recent studies 
have unraveled cardiac resident macrophages as a critical mediator for normal cardiac 
function. Macrophages within the heart exert phagocytosis and efferocytosis, facilitate 
electrical conduction, promote regeneration and remove cardiac exophers to maintain 
homeostasis. These findings underpin the rationale of introducing macrophages to 
engineered heart tissue, to more aptly capitulate in vivo physiology. Despite the lack of 
studies using cardiac macrophages in vitro, there is enough evidence to accept that they 
will be key to making engineered heart tissues more physiologically relevant. In this 
review, we explore the rationale and feasibility of using macrophages as an additional cell 
source in engineered cardiac tissues. 
  
























































































































































































Macrophages play a critical role in cardiac homeostasis and in disease. Over the last 
decade, we have come to understand the many vital roles played by cardiac resident 
macrophages in the heart, including immunosurveillance, regeneration, electrical 
conduction and elimination of exophers. There is a need to improve our understanding of 
the resident macrophage population in the heart in vitro, to better recapitulate the 
myocardium through tissue engineered models. However, obtaining them in vitro remains 
a challenge. Here, we discuss the importance of cardiac resident macrophages and 
potential ways to obtain cardiac resident macrophages in vitro. Finally, we critically discuss 
their potential  in realizing impactful in vitro models of cardiac tissue and their impact in 
the field.  
  
























































































































































































Macrophages are present in almost every vertebrate tissue. They contribute to the 
maintenance of immunity by phagocyting microbes, clearing senescent cells and 
promoting homeostasis by repairing and regulating the functions of organs. Initially 
perceived as a cell population only present in, and originating from the blood, recent 
studies have brought to light the stark heterogeneity in blood-derived and a pre-natal 
embryologically derived macrophage populations. Most tissues in the body contain a 
resident macrophage population exhibiting diverse phenotypes, specific to that tissue and 
niche1. This phenotypic heterogeneity is potentially due to the impact of the resident 
tissue environment as well as to differences in the macrophage origin2. However, despite 
being best known as the key mediators in tissue defense, the exact role of different 
subsets of resident macrophages in protecting the body from pathogens or environmental 
change are still unclear, as they are hard to extract, purify and study in vitro.  
The focus of this review, cardiac resident macrophages;  originate during embryogenesis 
and populate the heart prenatally3. Only within the past 3-4 years, seminal studies 
unravelling the functions and the physiological importance of cardiac macrophages have 
emerged (in mice), identifying these cells as a potential candidate in tissue engineering 
applications. In addition to performing critical functions in healthy myocardium, cardiac 
resident macrophages respond uniquely to subtle changes in the homeostatic equilibrium. 
Although there has been a limited number of studies focusing on the role of resident 
macrophage populations in the heart, there exists enough groundwork to explore the 
possibilities of achieving more humanized cardiac tissue models using resident 
macrophages. Additionally, by incorporating resident macrophages within engineered 
heart tissues, models can be more physiologically relevant, with applications in 
regenerative medicine, disease modelling and drug screening. However, there remain a lot 
of questions to be answered - what degree of these cells are lost during myocardial 
disease/ischemia; how do they function in response to injury and disease, and what role 
do their paracrine factors exert in tissue engineered models, to name but a few. We 
discuss cardiac macrophages in healthy myocardium, and during myocardial infarction (MI) 
and post-MI heart failure. We recap on the various engineered heart tissue (EHT) models 























































































































































































that have emerged over the years and discuss the potential applications of macrophages 
within such models in cardiac tissue engineering. Finally, we discuss the challenges of 
obtaining cardiac resident macrophages in vitro, and avenues of obtaining them in vitro for 
tissue engineering - such as using induced pluripotent stem cell (iPSC) derived 
macrophages (iMacs), opening up the possibility to study genes and genetic pathways 
involved in their function.  
Macrophage Populations in the heart and their functions 
The cellular content of human myocardium (in descending order by number) 
predominantly consists of cardiomyocytes, fibroblasts, pericytes and smooth muscle cells, 
endothelial cells and immune cells4. In the murine heart, macrophage populations can be 
discerned based on their expression of C-C chemokine receptor type 2 (CCR2), major 
histocompatibility complex-II (MHC-II), T-cell immunoglobulin and mucin domain 
containing 4 (TIMD4) and Lymphatic Vessel Endothelial Hyaluronan Receptor 1 (LYVE1). 
Four populations of macrophages have been identified in the murine heart5 (Fig.1). The 
minority are two subsets of CCR2+MHC-IIhigh macrophage populations derived from 
hematopoietic stem cells (HSCs), whereas the most dominant subset, cardiac resident 
macrophages derived from the yolk sac, are CCR2-MHC-IIlowTIMD4+LYVE1-. There also 
exists a fourth subset that consists of CCR2-MHC-IIhighTIMD4+LYVE1+ macrophages which 
are likely derived from CCR2-MHC-IIlow macrophages during postnatal development5, 6 and 
partially maintained by CCR2+MHC-IIhigh macrophages. CCR2+MHC-IIhigh macrophages 
populate the heart soon after birth and are maintained through monocyte recruitment 
and proliferation7. Also, under homeostasis, cardiac macrophages continually self-renew 
with a turnover period of almost five weeks8. Recently this same CCR2+ and CCR2- 
macrophage distinction has been identified in humans9, with the yolk sac-derived CCR2- 
human counterpart showing  CD14+CD45+CD64+CCR2-HLA-DRhigh expression5, 9. In a more 
recent study, Tucker et al. reported two cardiac macrophage subsets within the human 
heart which were positive for CD163, COLEC12, mannose receptor MRC1, E3 ubiquitin 
ligase MARCH1 and natural resistance–associated macrophage protein 1 (NRAMP1). While 
both of the identified subsets express anti-inflammatory (M2) polarization–associated 























































































































































































genes, one subset particularly expressed RBPJ, F13A1 and the other expressed 
transmembrane collagen COL23A110. 
CCR2+ and CCR2- macrophage populations are present in specific locations within the 
heart, performing distinct functions. CCR2+ macrophages are usually found in the 
trabecular projections of the heart and their role in cardiac development has not been 
fully delineated. However, they are activated when homeostatic balance is interrupted- 
such as during a disease11. In contrast, CCR2- macrophages, herein referred to as cardiac 
resident macrophages, occupy the myocardial wall and play a principal role in normal 
coronary development and maturation12. However, such studies are mostly limited to 
murine models. In addition to demonstrating robust phagocytic behavior13, cardiac 
resident macrophages have demonstrated a role in neonatal cardiac regeneration in mice, 
salamanders and zebrafish14-16, potentially through the stimulation of angiogenesis17.  
Furthermore, cardiac resident macrophages interact very closely with cardiomyocytes and 
form signaling complexes through connexin-43 allowing synchronous depolarization18 
(Fig.2). Hulsmans et al. have shown that depletion of either cardiac resident macrophages 
or connexin-43 effects a delay in conduction and blockage in the atrioventricular node in 
mice. This study highlights a critical role of cardiac macrophages in coupling with 
cardiomyocytes to facilitate electrical conduction within the heart. Undoubtedly, the 
coupling of cardiomyocytes and cardiac resident macrophages holds a lot of possibilities in 
regenerative medicine, to be explored in the future.  
In addition to their involvement in the conduction system of the heart, cardiac 
macrophages also play a role in phagocytosis and efferocytosis19 (Fig.2). Cardiac 
macrophages express high levels of myeloid epithelial reproductive tyrosine kinase 
(Mertk), which plays a role in macrophage-mediated efferocytosis. In the absence of this 
protein, cell debris removal during cardiac repair is severely affected, resulting in increased 
infarct size and reduced cardiac function20. Removal of debris and other materials ejected 
by cardiomyocytes is crucial in maintaining adequate cardiac function even in non-
pathological settings. Similar to  how the central nervous system disposes of dysfunctional 
organelles21, cardiomyocytes remove dysfunctional subcellular particles with the help of 
cardiac resident macrophages22. Likewise, Nicolas-Avila et al. documented that 























































































































































































cardiomyocytes, which are continuously contracting and metabolically active cells, release 
subcellular particles termed “exophers” containing defective mitochondria22. These 
exophers are taken up by cardiac resident macrophages through Mertk to maintain cardiac 
homeostasis. This maintenance role of cardiac resident macrophages is further 
demonstrated when they are depleted in the myocardium (by intraperitoneal injection of 
10 µg/kg diphtheria toxin in mice)22, which in turn reduces the presence of these exophers, 
delineating the role of cardiac resident macrophages in maintaining normal cardiac 
autophagy. In addition to unveiling this unique role of cardiac resident macrophages, this 
is the first study to show that myocardial tissue releases exophers (in mice). 
Macrophage Populations during MI and post-MI heart failure 
In the murine heart, the macrophages and monocytes population in the myocardium 
following an infarct is dramatically different from that in steady state (Fig.3). The temporal 
dynamics of leukocyte infiltration following surgically induced MI has been assessed using 
flow cytometry and determines that neutrophils are among the first leukocytes to reach 
ischemic heart tissue23. This migration of leukocytes to the ischemic site is mediated by C-
X-C motif chemokine ligand 2 (CXCL2) and CXCL5 production by CCR2+ macrophages24. 
Monocyte recruitment to the infarct site begins as early as 30 minutes depending on CCR2 
signaling, from both the bone marrow and the spleen, via MCP-1/CCR2 signaling25. This 
infiltration of monocytes and macrophages  to the infarcted tissue occurs in two phases23. 
The Ly-6Chigh monocytes exhibiting pro-inflammatory phenotype predominate the early 
days (marking the first phase), peaking on day 3 23 (Fig.3). Around 40% of the infiltrating 
Ly-6Chigh monocytes in the first 24hrs post-MI are from the splenic monocyte reservoir26. 
During this period, also known as the inflammatory phase, macrophages and neutrophils 
clear dead cells and debris. After proper resolution of the inflammatory phase, there 
occurs a phenotypic transition from Ly-6Chigh monocytes to Ly-6Clow monocytes and M2 
macrophages which exert reparative functions and renew locally26. Ly-6Clow macrophages 
predominate the later stages as inflammation resolves (marking the second phase), 
peaking between days 5 to 7 post-infarct27 (Fig.3). Similarly, the remote myocardium also 
undergoes a sequential Ly-6Chigh to Ly-6Clow differentiation pattern, with the Ly-6Clow cells 
peaking 5 days later than at the infarct28. The cardiac resident macrophages in the infarct 























































































































































































area die shortly after MI6. However, more recent studies show that in the post-MI phase, 
the majority of the cardiac resident macrophages proliferate locally with a minor 
contribution from blood-derived monocytes6.  
During the inflammatory phase, classically activated (M1) macrophages secrete cytokines 
such as tumor necrosis factor α (TNFα), interleukin (IL)-1β, IL-6 and matrix 
metalloproteinases (MMPs) to facilitate extracellular matrix (ECM) breakdown29. 
Phagocytosis mediated by M1 macrophages is crucial for the initiation of the wound 
healing process. However, prolonged production of these inflammatory cytokines could 
lead to a number of pathological consequences including cardiomyocyte death, cardiac 
rupture, fibrosis, dilated cardiomyopathy due to matrix degradation etc.30. For example, 
TNFα (produced by macrophages, cardiomyocytes and endothelial cells) induces 
cardiomyocyte hypertrophy which can lead to post-MI heart failure31. Over the following 
days, macrophages promote fibroblast differentiation into myofibroblasts which express 
smooth muscle actin and lay down collagen, contributing to scar formation32. Additionally, 
vascular endothelial growth factor (VEGF) and transforming growth factor-β (TGF-β) 
produced by the macrophages facilitate revascularization of tissues23, 33. Finally, 
macrophages also produce MMPs that help in breaking down the ECM and promote tissue 
remodeling.  
Any abnormalities in either of the phases can be detrimental to the cardiovascular system. 
In particular, macrophage depletion is deleterious to infarct healing and worsens the 
remodeling process34, 35. Despite being merely 2-5% of the total macrophage population in 
the heart in the initial weeks post-MI, the depletion of cardiac resident macrophages 
impaired normal infarct healing and adversely affected the remodeling process5. Shirishi et 
al. demonstrated the effect of inactivation of alternatively activated (M2) macrophages 
post-MI by using a mouse model with Trib1 gene deletion36. The impaired wound 
remodeling was rescued by the introduction of M2 macrophages exogenously. 
Additionally, limiting the number of infiltrating monocytes via CCR2 blockage has shown to 
decrease the infarct size in MI recovery animal models37-39, demonstrating the relevance of 
therapeutic approaches to limit infiltrating monocyte numbers is patients with increased 
systemic inflammatory activity to improve post-MI recovery.  























































































































































































As mentioned previously, initial fibrosis following MI is necessary to facilitate scar 
formation and initiate tissue remodeling. However, extensive fibrosis can result in morbid 
cardiac remodeling and heart failure40. The macrophage number in the heart progressively 
increases from the onset of MI to heart failure, with local proliferation as well as 
recruitment responsible41. While macrophages in the remote myocardium increase, their 
number depletes at the site of infarct6. This local expansion of cardiac macrophages 
aggravates the progression of heart failure by producing factors that promote fibrosis, 
such as TGF-β, platelet derived growth factor and angiotensin-II42. Myofibroblasts and 
cardiomyocytes also further prompt TGF-β production causing adverse remodeling that 
leads to heart failure. The detrimental effects of recruited monocytes/macrophages are 
further recognized as splenectomy reduces infiltrating macrophages and improves cardiac 
function43. A recent report also suggested that mechanical strain can trigger macrophage 
proliferation by activating mitogen activated protein kinase (MAPK) pathway, 
demonstrating that increased higher mechanical strain in failing heart could stimulate 
macrophage expansion6. These evidences further highlight the ill impacts of infiltrating 
macrophages in the infarcted heart. It is also of importance to note recent studies 
suggesting that the opportunity for successful regeneration of the heart after MI is 
restricted to 3 days post-MI and is potentially mediated by cardiac resident macrophages 
and fibroblasts44.  
Engineered Heart Tissue Models  
Tissue engineering considerably enables our understanding of disease biology and 
possibilities for therapeutic intervention45. As opposed to 2D cell culture models, tissue 
engineered cardiac models provide the benefit of mimicking in vivo myocardium, with the 
additional functional benefit of tissue contraction, which is inherent to cardiac function46. 
Moreover, it also comes with the ethical benefit of using lesser number of animals. 
Engineered constructs are typically generated using primary cardiomyocytes (adult, 
neonatal, fetal), as well as cardiomyocytes obtained through iPSCs or embryonic stem cells 
(ESCs)47. Although engineered heart tissues (EHTs) can be fabricated purely using 
cardiomyocytes, the contractile function and the complexity of native myocardium is 























































































































































































better recapitulated with the addition of non-myocytes such as fibroblasts and endothelial 
cells48. Other non-myocytes that have been explored include cardiac stem cells49.  
Over two decades ago, the first EHT model was fabricated with chick embryonic 
cardiomyocytes mixed with Matrigel which anchored on to opposite ends of two Velcro 
coated glass tubes50 (Fig.4). This culture provided mechanical strain to the engineered 
tissue and hence was utilized as a platform for understanding the effects of uniaxial and 
multiaxial stretching, growth factors, cardiomyocyte maturation etc. This same principle 
was used to modify the geometry of the EHT to obtain a ring-shaped model which 
supported mammalian (rat) cardiomyocytes and also facilitated long-term force 
measurements51, 52. Although a number of different scaffold-based cardiac tissue 
engineered models were developed around this period, the next major modification to the 
EHT design was miniaturized EHTs made with fibrin, that were adapted to 24-well format, 
to facilitate drug screening53. This study demonstrated the use of video-optical recording 
for the measurement of contractility of the tissues, which is a commonly used method of 
contractility measurement at the moment53. Shortly after, Boudou et al. generated 
collagen/fibrin matrix-based cardiac microtissues using microfabricated tissue gauges that 
incorporate microelectromechanical systems (MEMS) cantilevers54. This facilitated in 
simultaneously constraining and reporting forces generated by the tissues in real time54. 
Similar approaches with cantilevers to allow tissue anchorage has also been used by 
Turnbull et al. to facilitate fabrication of potential preclinical in vitro myocardium models55. 
Another interesting modification to the EHT came with the use of a surgical suture within 
PDMS molds to obtain aligned cardiac tissues with striations called ‘Biowire’56. Following 
this study, Bian et al. demonstrated that fabricating cardiac tissues with longer elliptical 
pores within the patch networks improve ECM alignment within the patch57. In the past 5 
years, the field of EHTs further underwent drastic advances where fibrin based EHTs under 
dynamic culture (using platform rockers) showed improvement in tissue maturation58. 
These EHTs, called ‘cardiobundles’ were designed to be cylindrically shaped and anchored 
within porous flexible nylon frames that supported chronic auxotonic loading and free-
floating culture of the tissues58. More recently, the advanced successor of Biowire, named 
‘Biowire II’, a heteropolar cardiac tissues containing distinct atrial and ventricular ends was 























































































































































































generated59. This heteropolar tissue formation was achieved using directed cell 
differentiation and electrical field conditioning59. With over two decades of input, one of 
the most recent advancement in EHTs is a mesh structured EHT patch of dimension 5 x 
7cm, that closely resemble human ventricular tissue60.  
One of the key features of EHTs is their ability of respond to drugs. Most of the different 
types of EHTs fabricated over the years aim to feature their drug response. For example, 
over a decade ago, Hansen et al. showed that EHTs display a concentration-dependent 
increase in relaxation time on treatment with chromanol, quinidine, and erythromycin, 
while doxorubicin treatment resulted in decreased contractile force 53. Similarly, Boudou 
et al. tested isoproterenol and digoxin on their EHTs to understand the functional 
consequences of pharmacologic agents54. They showed that small doses (10 and 100 nM) 
of isoproterenol increased the contractility of the EHTs while 1 and 10 mM decreased the 
contractility54. On the other hand, digoxin improved the contractility at 1 nM and 1 mM 
but was found to be cardiotoxic at 10 mM concentration54. Hence, the varied and dose 
dependent sensitivity of EHTs towards different drugs make them an exciting alternative 
to animal models in addition to being a useful tool in understanding the effect of various 
drugs on the myocardium. Despite the proven efficacies of these EHTs, there still remain 
challenges in making them more humanized, including the addition of right cell types to 
mimic the complexity of the myocardium. For a more detailed review capturing EHT the 
reader is referred to the paper by Christian Zuppinger 61. One of the potential additions to 
improve the response of EHTs would be cardiac resident macrophages, as they are critical 
in the normal functioning of the heart.  
Macrophages in Tissue Engineering 
In recent years, the critical importance of incorporating macrophages into engineered 
constructs is being recognized62,63 and aside from the immunological responses of host 
macrophages, their role has been harnessed in a number of tissue engineering approaches 
to improve tissue maturation, repair and regeneration64. Understanding macrophage 
responses during biomaterial design65, 66, as well as exploring the effects of mechanical 
cues on macrophage polarization are other areas within tissue engineering that have 
gained attention67, 68. Researchers have studied the potential of immune assisted tissue 























































































































































































engineering, by incorporating macrophages into tissue engineered constructs (Table 1). In 
particular, macrophages have been used to vascularize biomaterials69, by promoting 
angiogenesis70 and vessel formation71. Although immune assisted tissue engineering has 
not been largely investigated, these data show the significance of macrophages in various 
tissue engineered constructs. 
Within cardiac tissue engineering, the specific functional requirement of this tissue 
includes contraction, which is inherent to cardiac function46. As macrophages have been 
shown to be integral during signal propagation (See Fig.2), their inclusion in engineered 
tissue could facilitate robust and more physiologically accurate contraction mechanics. 
Engineered constructs are typically generated using of primary cardiomyocytes (adult, 
neonatal, fetal), as well as cardiomyocytes obtained through iPSCs or embryonic stem cells 
(ESCs)47. Since the critical role played by macrophages in cardiac regeneration, 
maintenance of homeostasis and disease progression has been recognized (in mice), 
cardiac tissue engineering has begun to focus on incorporating macrophages into 
engineered heart tissues to recapitulate native tissue functions. A pioneering in vitro study 
in which human peripheral blood-derived macrophages and iPSC-derived cardiomyocyte 
interaction was assessed, attempted to recapitulate critical cellular events during 
myocardial injury, using a 3D inversion assay. They proposed a bone morphogenetic 
protein (BMP) mediated crosstalk between these two cell types72. Cardiomyocyte-derived 
BMP promoted pro-inflammatory (M1) macrophage recruitment and M1 macrophage-
derived BMP improved cardiomyocyte proliferation and differentiation potential. This 
proposed paracrine mechanism of BMPs was new and provided a new insight into the 
mechanism of interaction between cardiomyocytes and peripheral blood-derived 
macrophages. Interestingly, a recent study has shown that the presence of macrophages in 
engineered cardiac tissue facilitates cardiomyocyte de-differentiation and remodeling73. In 
this study, it was observed that during the initial days (up to 3 days), the macrophages in 
the engineered cardiac tissue were polarized to an M1 state (CD86 positive), followed by a 
predominance of M2 macrophages (CD206 positive) as the cardiomyocytes de-
differentiated. The effects of macrophage activity on the engineered cardiac tissue model 
could not be explained in this study however, as a heterogenous population of whole cells 























































































































































































from rat heart was used to make the engineered cardiac tissue. Nonetheless, future 
studies into the influence of macrophage populations of different ontological origin on 
cardiac function will shed light on their potential role in cardiac tissue engineering.  
One study, by Wrona et al. explored the response of human hESC-derived cardiomyocytes 
to peripheral blood derived monocytes, with a focus on investigating the effects of 
polarized macrophages and their activation inducing cytokine profiles on cardiomyocyte 
function74. In this study the gene expression profile of the macrophages remained 
unaffected upon exposure to hESC-derived cardiomyocytes while cardiac-specific genes 
were downregulated on exposure to M1 and M2 polarized macrophages74. Tying in with 
the findings of this work, a study by Hitscherich et al. using murine ESC-derived 
cardiomyocytes also showed a decrease in the expression of cardiac-specific genes such as 
cardiac troponin T and sarcoplasmic/endoplasmic reticulum calcium ATPase when cultured 
with conditioned media from M1 polarized blood-derived murine macrophages75. Here a 
co-culture system was employed, to demonstrates that M1 macrophages promoted a 
higher Ca2+ fractional release and both macrophage subtypes downregulated the store-
operated Ca2+ entry in murine ESC-derived cardiomyocytes. As discussed previously, EHTs 
and other scaffold-based tissue engineered models for the myocardium heavily rely on 
cardiomyocytes, cardiac fibroblasts and endothelial cells to represent the myocardium. 
Although literature shows the potential of EHTs in guiding us towards obtaining robust in 
vitro models of human myocardium that has the ability to mature, beat in synchrony and 
respond to drugs, the addition of macrophages into these models could benefit our 
understanding on the in vitro behavior of macrophages in a complex, multicellular 
humanized setting. From the available in vivo studies (in mice), it could be anticipated that 
the incorporation of cardiac resident macrophages within an EHT (containing 
cardiomyocytes) will facilitate improved contractility and electrical conduction of the 
tissue. Additionally, the tissue could be hypothesized to exhibit improved maturity as there 
could be constant exophers elimination and maintenance of homeostasis.  
Another interesting avenue that can be pursued using an EHT model that incorporates 
cardiac resident macrophages is screening anti-inflammatory drugs for post-MI treatment. 
Although clinical studies on drug treatment in MI patients is limited, there are a number of 























































































































































































drugs that have been developed for regulating immune response post-MI76. This includes 
non-steroidal anti-inflammatory drugs, glucocorticoids, cyclosporine etc77. Despite 
showing an improvement in mortality, these broad anti-inflammatory drugs often fail to 
provide a cardio-protective effect77. To circumvent this limitation, targeted anti-
inflammatory drugs can be used. For example, the CANTOS (Canakinumab Anti-
Inflammatory Thrombosis Outcomes Study) trial was the first large cardiovascular clinical 
trial to target the inhibition of inflammation by using the drug canakinumab, which inhibits 
IL-1β to subsequently reduce the production of IL-6 and high sensitivity C-reactive protein 
(hsCRP)78.  Among the 10,061 patients with previous MI and hsCRP level ≥ 2mg/l, patients 
treated with 150 and 300 mg of canakinumab experienced a 15% reduction in major 
adverse cardiovascular events in comparison with placebo78. Although canakinumab was 
not ultimately approved for cardiovascular treatment, CANTOS trial demonstrated that 
targeting the inflammatory pathway involving IL-1β and hsCRP reduces adverse 
cardiovascular events. CANTOS was followed by CIRT (Cardiovascular Inflammation 
Reduction Trial) in which 4786 patients with stable atherosclerosis with diabetes mellitus 
or metabolic syndrome were subjected to low-dose methotrexate79. Low-dose 
methotrexate failed to reduce major adverse cardiovascular events, and also failed to 
reduced plasma levels of IL-1β and hsCRP, further demonstrating the importance of 
adequate inhibition of IL-1β to IL-6 pathway for long-term cardiovascular benefits80. 
Further large cardiovascular outcome trials targeting the inflammatory pathways that 
followed includes COLCOT (Colchicine Cardiovascular Outcomes Trial)81 and LoDoCO2 (Low 
Dose Colchicine after Myocardial Infarction)82. Both of these trials used low doses of 
colchicine (0.5mg/day), which is a repurposed anti-inflammatory agent. While COLCOT had 
4745 patients with recent MI (less than 30 days), LoDOCO2 had 5522 patients with chronic 
coronary artery disease and both the studies showed reduction in the incidence of adverse 
cardiac events such as MI, stroke, cardiovascular death etc81, 82. However, colchicine being 
associated with increase in pneumonia, nausea and flatulence poses risk80. To that end, 
the lack of success for most of these drugs could also stem from the fact that they are not 
thoroughly validated in vitro prior to human trial. The trajectory of recent and ongoing 
cardiovascular outcome trials show an increased interest towards novel anti-inflammatory 
and anti-cytokine drugs80. This further demonstrates the benefit of an in vitro model of the 























































































































































































myocardium that has innate immune cells (especially macrophages) as they serve as the 
primary target for these drugs and can potentially fill the gap between the patient and the 
pharmaceutical industry.  
iPSC and ESC-derived macrophages 
Obtaining human cardiac macrophages for subsequent in vitro studies is challenging. To 
date, macrophage studies have heavily relied on murine or human blood-derived 
monocytes but these cells are not ideal for appropriating tissue resident phenotypes due 
to their vast transcriptomic and epigenetic variations, as well as difference in origin 
between blood-derived and resident macrophages83. Obtaining primary resident 
macrophages from vital organs (cardiac macrophages, Kupffer cells, microglia etc.) is not 
feasible, as acquiring tissue samples from healthy donors is often associated with donor 
site morbidity, in addition to ethical considerations. To circumvent these limitations, the 
use of iPSCs and hESCs as macrophage progenitor sources has come to the forefront (Fig.5) 
(Table 2). Over the last decade, a number of different protocols have been established for 
stem cell culture and differentiation, to obtain CD14highCD16lowCD163+CD11b+ 
macrophages, morphologically similar to blood-derived macrophages84-88. Critically, iPSC 
and hESC-derived macrophage sources have shown therapeutic benefits in ameliorating 
liver fibrosis89, acute lung injury90 and are also under clinical trial for liver cirrhosis91.  
Furthermore, recent studies have shown that iMacs share ontogeny with tissue resident 
macrophages and are independent of MYB90, 92, 93, suggesting that iMacs in isogenic co-
cultures may offer a facile and effective approach to obtaining physiologically relevant 
resident macrophages94. For example, iMacs in co-culture with neural cells were found to 
become microglia-like cells95, 96. Haenseler et al. showed that iMacs in co-culture with iPSC-
derived neurons, expressed markers relevant to microglia as well as major 
neurodegenerative disorders84. Similarly, iMacs in co-culture with hepatocytes were found 
to show Kupffer cell-like characteristics93.  
In addition to co-culture models, the effect of the local biochemical environment on the 
specialization of tissue-resident macrophages is becoming more evident in regenerative 
medicine. Certain transcriptional factors regulate the expression of tissue-resident 























































































































































































macrophages97, such as Spi-c for the development of the red pulp macrophages in 
spleen98, Sall1 for microglia99,  and Id3 for Kupffer cells100.  In a more recent study, 
activation of iMacs with transcriptional factor KLF1 was found to drive them towards an 
erythroblastic island like phenotype101. These studies demonstrate that physiologically 
relevant resident macrophages could be obtained in vitro by providing tissue specific cues 
or by activating specific transcriptional factors. Although, cardiac resident macrophages 
have not yet been derived from iPSCs, research is proceeding in the right direction, paving 
way to understanding optimal methods of cardiac resident macrophage acquisition in 
vitro, such as using primary cardiomyocyte conditioned media on iPSC-derived 
macrophages, establishing co-culture models of cardiomyocytes and iPSC-derived 
macrophages or using bioinformatics tools to determine transcriptional factors for their 
induction. Taken together, iPSC-derived macrophages offer great potential in 
understanding and modelling tissue resident macrophages.  
Conclusion 
From regarding macrophages as a system of clearing dead cells, to appreciating their role 
in tissue defense, homeostasis, regeneration and organ development, our understanding 
of macrophages has advanced significantly in recent years. Lineage tracing and fate 
mapping studies demonstrated that most vital organs are largely populated by resident 
macrophages at the onset of embryological development and play critical roles in health 
and disease. Within the heart, resident macrophages ensure homeostatic cardiac function 
by performing a number of vital functions including phagocytosis, efferocytosis, 
eliminating exophers, facilitation of electrical conduction etc. Our understanding of cardiac 
immunology has progressed well enough to regard cardiac resident macrophages a 
potential candidate to include in engineered heart tissues, to further our understanding of 
cell interactions in addition to making the engineered tissues more physiologically 
relevant. But much more still remains to be understood, such as what degree of these cells 
are lost during myocardial disease/ischemia; how do they function in response to injury 
and disease, their paracrine effects in tissue engineered models etc. The next step in 
cardiac tissue engineering is to unravel the crosstalk between cardiac macrophages and 
cardiomyocytes in vitro and further our understanding the molecular processing involved 























































































































































































in their interaction and their potential in regenerative medicine, therapeutics, disease 
modelling and drug screening. With engineered heart tissues gaining great research 
interest, it is highly pertinent to include a resident macrophage population to make the 
tissue more physiologically relevant. By building on our strong foundational knowledge on 
different macrophage populations and with the assistance of new technologies, we will 
hopefully see rapid progress in finding new therapeutics using cardiac tissue engineering. 
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Fig.1 Macrophage subsets in human and mouse and their origin. Cardiac macrophages 
populate the heart prenatally from the embryonic yolk sac, while bone marrow-derived 
macrophages enter the heart two weeks after birth. In humans, the macrophage 
populations are distinguished based on the presence of CCR2, as CCR2-HLA-DRhigh (cardiac 
macrophages) and CCR2+HLA-DRhigh (bone marrow-derived macrophages). The three 
distinct populations of macrophages in murine heart are, CCR2-MHC-IIlow (cardiac 
macrophages), CCR2-MHC-IIhigh (derived postnatally from cardiac macrophages), 
CCR2+MHC-IIhigh (bone marrow-derived macrophages). Created with BioRender.com 
  
























































































































































































Fig.2 Functions of cardiac macrophages in healthy myocardium. In steady state, cardiac 
macrophages perform several important functions in the myocardium. One of their major 
functions is to facilitate electrical conduction by coupling with cardiomyocytes through 
connexin-43 gap junctions. They help in sustaining normal cardiac autophagy by capturing 
and eliminating exophers (containing defective mitochondria) released by cardiomyocytes, 
through Mertk. They also perform immunosurveillance and clear dead cells and debris in 
the myocardium, to maintain homeostasis. The presence of cardiac macrophages is found 
to be essential in promoting cardiac regeneration.  Created with BioRender.com 
  
























































































































































































Fig.3 Macrophage origin and function in infarcted heart. After MI, the monocytes that 
infiltrate the heart originate from bone marrow (~60%) and spleen (~40%). The 
recruitment of bone marrow-derived monocytes is CCR2 dependent and that of spleen-
derived monocytes is angiotensin II-dependent. Cardiac resident macrophages reside, self-
renew and carry out a number of functions in the myocardium. However, at the infarct site 
and remote myocardium, infiltrating macrophages differentiate to M1 and M2 
macrophages in response to different cues, and secrete pro-inflammatory and pro-healing 
factors based on their macrophage phenotype. The number of M1 and M2 macrophages 
peak in the infarct site and remote myocardium at different pace. Created with 
BioRender.com 
  
























































































































































































Fig.4 Brief overview of the evolution of Engineered Heart Tissues. The very first EHT was 
generated in 1997 using chick embryonic cardiomyocytes on Velcro coated glass tubes50. 
This model and the geometry of EHTs evolved over the years, from ring-shaped EHTs51 to 
mini-EHTs adapted to 24 well plate format53, to EHTs with fluorescent cantilevers that can 
track contractile motions54, followed by Biowire56, cardiobundles58 and Biowire II59, to 
finally reach human-scale EHT patch60. Created with BioRender.com 
  
























































































































































































Fig.5 Macrophage derivation from iPSCs and their applications. iPSCs can be derived from 
human beings by reprogramming somatic cells (fibroblasts, blood cells etc.). On specifying 
the mesodermal origin, they can be differentiated into macrophages. Cardiac resident 
macrophages can potentially be obtained by giving iPSC-derived macrophages tissue 
specific cues or activating specific transcriptional factors. These macrophages can be used 
for a number of applications such as disease modelling, cell therapy, genomics (to identify 
new genes) and drug testing. Created with BioRender.com 
  
























































































































































































Table 1 Examples of macrophage use in tissue engineering 
Tissue Macrophage  Application 
Bone Blood-derived macrophages Vascularization of scaffold69 
Blood-derived macrophages Osteogenesis102, 103 
Skeletal muscle Blood-derived macrophages Regeneration63 
Blood vessel Blood-derived macrophages Vascularization of scaffold71 
Liver Kupffer cells Hepatotoxicity104 
Kupffer cells Disease-drug interaction105 
Nerve Microglia Regeneration106 
Brain/spinal cord Microglia Understand cellular crosstalk during 
neuroinflammation107 
Lungs Alveolar macrophages Understanding response to 
atmospheric particles108 
Alveolar macrophages In vitro lung inflammation 
platform109 





























































































































































































Table 2. Examples of iPSC-derived macrophage subsets and their respective phenotypic 
markers 
Tissue Cell-type  Phenotypic markers 
Blood Blood-derived 
macrophages 
CD18+, CD11b+, CD11c+, CD14+, CD16+, CD115+, 
CD1a-, CD83-, CD3-, CD19-111 
CD14+, CD16+, CD163+, CD86+112  
CD45+, CD11b+, CD14+, CD163+, CD68+113 
Lungs Alveolar 
macrophages 
CD80+, SIRPa+, MHCII-, Langerin-90 
Liver Kupffer cells CLEC-4F+, ID1+ and ID3+ 93 
 
Brain Microglia IBA1+, CD11c+, TMEM119+, P2RY12+, CD11b+, and 
CX3CR1+114 



























































































































































































Table 1 Examples of macrophage use in tissue engineering 
Tissue Macrophage  Application 
Bone Blood-derived macrophages Vascularization of scaffold52 
Blood-derived macrophages Osteogenesis55, 56 
Skeletal muscle Blood-derived macrophages Regeneration46 
Blood vessel Blood-derived macrophages Vascularization of scaffold54 
Liver Kupffer cells Hepatotoxicity57 
Kupffer cells Disease-drug interaction58 
Nerve Microglia Regeneration59 
Brain/spinal cord Microglia Understand cellular crosstalk 
during neuroinflammation60 
Lungs Alveolar macrophages Understanding response to 
atmospheric particles61 
Alveolar macrophages In vitro lung inflammation 
platform62 




























































































































































































Table 2. Examples of iPSC-derived macrophage subsets and their respective phenotypic 
markers 
Tissue Cell-type  Phenotypic markers 
Blood Blood-derived 
macrophages 
CD18+, CD11b+, CD11c+, CD14+, CD16+, CD115+, 
CD1a-, CD83-, CD3-, CD19-89 
CD14+, CD16+, CD163+, CD86+90  
CD45+, CD11b+, CD14+, CD163+, CD68+91 
Lungs Alveolar 
macrophages 
CD80+, SIRPa+, MHCII-, Langerin-78 
Liver Kupffer cells CLEC-4F+, ID1+ and ID3+ 81 
 
Brain Microglia IBA1+, CD11c+, TMEM119+, P2RY12+, CD11b+, and 
CX3CR1+92 
CD11b+, ITGB2+, CSF1R+, CD45+, IBA1+ and 
ADORA3+93 
 
